SCHEMBL946496

SCHEMBL946496

CC(C)(C)OC(=O)N1CCC(CCn2cnc3c2CCCC3)CC1

nearest known ligand 0.46

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.46
GPR119 Q8TDV5 16/20 0.46
KDM4E B2RXH2 1/20 0.43
PKM P14618 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL948286 0.80 FAAH (0.49) FAAHGPR119KDM4EPKM
SCHEMBL948271 0.78 GPR119 (0.43) FAAHGPR119KDM4EPKM
SCHEMBL948342 0.75 GPR119 (0.52) FAAHGPR119KDM4EPKM
SCHEMBL3751306 0.74 PI4KA (0.50) FAAH
SCHEMBL21855580 0.74 GPR119 (0.42) FAAHGPR119KDM4EPKM
SCHEMBL6152184 0.74 HPGD (0.56) FAAHGPR119KDM4EPKM
SCHEMBL3740474 0.74 GPR119 (0.44) FAAHGPR119KDM4EPKM
SCHEMBL949087 0.73 GPR119 (0.50) FAAHGPR119KDM4EPKM
SCHEMBL30171174 0.73 MAPT (0.43) FAAHGPR119
SCHEMBL30171154 0.73 CNR2 (0.45) GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110009389-A1 IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-01-13 US disclosed
US-20070004736-A1 Imidazole derivative, process for producing the same, and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-01-04 US disclosed
EP-1564213-A1 IMIDAZOLE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Pharmaceutical Company Limited (JP) 2005-08-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004736-A1 Imidazole derivative, process for producing the same, and use HRH4, F2, HRH2 FAAH 1246/4885GPR119 1327/4885KDM4E 1356/4885
US-20110009389-A1 IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE F2, H1-3, CYC1 FAAH 1524/4885GPR119 1118/4885KDM4E 1558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.